Join to View Full Profile
3601 The Vanderbilt ClinicNashville, TN 37232
Phone+1 615-322-3000
Dr. Pauff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2013 - 2016- Vanderbilt University Medical CenterResidency, Internal Medicine, 2011 - 2013
Ohio State University College of MedicineClass of 2011
Certifications & Licensure
TN State Medical License 2012 - 2025
WI State Medical License 2016 - 2023
IL State Medical License 2016 - 2020
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer Start of enrollment: 2021 Feb 23
Publications & Presentations
PubMed
- A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies.Michal Kwiatek, Guru Subramanian Guru Murthy, Marc Hoffmann, Benoit Tessoulin, Alexey Danilov
Clinical Lymphoma, Myeloma & Leukemia. 2025-01-28 - 67 citationsTargeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myelomaJonathan L. Kaufman, Cristina Gasparetto, Fredrik Schjesvold, Philippe Moreau, Cyrille Touzeau
American Journal of Hematology. 2021-04-01 - 102 citationsSystematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.Benjamin F. Tillman, James M. Pauff, Gowri Satyanarayana, Mahsa S. Talbott, Jeremy L. Warner
European Journal of Haematology. 2018-04-01
Abstracts/Posters
- Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel TherapiesJames M. Pauff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center StudyJames M. Pauff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory ...James M. Pauff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
